ClinicalTrials.gg
CompletedNCT04138433Updated May 11, 2023

Mechanisms Underlying Spoken Language Production

An interventional study of Real tDCS and Sham tDCS in Aphasia, Anomic, sponsored by University College London Hospitals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by University College London Hospitals · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Most of us take being able to communicate for granted. Anomia (word finding problems) after stroke can cause profound frustration and anxiety for patients and families. Some people recover; many don't. \~ 250,000 people in the UK have chronic speech and language problems post-stroke. This project will investigate how treatment for these people might be improved. The brain's speech areas can be stimulated using transcranial direct current stimulation (tDCS). The kit is simple; a battery powering electrodes placed on the scalp. Healthy people who had tDCS while naming pictures could find words quicker and their speech areas responded more efficiently. How it affects aphasic stroke patients' brain function is unknown.

Read the detailed description

All suitable participants will be living in the community and may have already consented to previous research projects and their details identified via the UCLH Aphasia Clinic run by the CI, which will act as an NHS PIC, or via the stroke volunteer database at the Wellcome Trust Centre for Neuroimaging, run by Professor Cathy Price (Research approved by the National Hospital of Neurology and Neurosurgery and the Institute of Neurology joint ethics committee, study number: NO32.

The initial approach to potential participants for this project will be made by The Chief Investigator Dr Jenny Crinion. If the participant agrees a member of the team will discuss with them the details of the project. Patient groups may be approached directly by the CI and RAs via stroke clubs etc. All participants will be formally consented at UCL.

Healthy subjects will be recruited by the CI and RAs via the volunteer database at the WTCN or ICN, and by asking relatives/carers of the patients if they wish to be involved (more likely to be matched for age and other factors). Potential participants in research databases have already consented to be approached for further research.

Part 1: Activation and modulation of residual inferior frontal gyrus (IFG) in aphasia

Aims: to examine connectivity within regions of the brain associated with spoken word retrieval (a "domain-specific" process) and more general cognitive control ("domain-general" processing) in aphasic stroke patients.

Hypotheses: following aphasic stroke a functionally selective network core for spoken word naming (i.e. domain specific for language) lies within (i) Broca's area, in patients with brain lesions sparing Broca's area (ii) right inferior frontal gyrus, in patients with damage to Broca's area.

Experimental design and predictions:

Patients with a chronic speech and language impairment (aphasia) following stroke will be divided into those with lesions affecting Broca's area, and those whose lesions lie elsewhere. They will receive brain stimulation, transcranial direct current stimulation (tDCS, which involves placing battery-operated electrodes on the participant's scalp), or sham stimulation, while completing an object naming task (to test domain-specific processing) and a non-linguistic task which measures performance related to domain-general cognitive processing. Both tasks will have "hard" and "easy" levels which are matched for difficulty across tasks. In the naming task, difficulty will be manipulated by providing different types of cues to assist with object naming. Extensive piloting of the stimuli and procedure in both healthy participants and aphasic stroke patients will ensure that the tests are suitable for the proposed research.

Participants will complete the experiment in an MRI scanner in order to measure brain activity in the domain-specific and domain-general neural networks during the linguistic and non-linguistic tasks.

List of all data to be collected

  1. Personal demographic data including: sex, age, contact details etc.
  2. Clinical data including: aphasic syndrome subtype, time since onset of symptoms, past medical history, current medications, contra-indications to MRI/fMRI/tDCS, etc.
  3. Language assessment scores (CAT).
  4. Naming scores.
  5. fMRI responses when speaking and at rest.
  6. High-resolution structural MRI scans to define area and volume of infarct
  7. Side-effects from stimulation/sham (Adverse Event data).
  8. Consent forms. The non-functional imaging data will be recorded on a Case Report Form (CRF) kept by the CI.

Collection/Storage

Any data initially collected on paper will be transferred to electronic format. The paper data (including a copy of the consent form) is stored in a locked cabinet at the ICN which only the CI and named collaborators will have access to. The electronic data is password protected and pseudoanonymized. The CI will be the custodian of the data after the trial is completed. Data will be kept for 10 years after the completion of the study, in line with UCL policy. The functional/structural imaging data (5, 6) will be stored indefinitely at the WTCN, this will be password protected. These are extremely rich data sets and may be used in future analyses/metanalyses. Only members of the research team will have access to the data. The CI will act as custodian of the data.

Monitoring and Auditing

The Chief Investigator will ensure there are adequate quality and number of monitoring activities conducted by the study team. This will include adherence to the protocol, procedures for consenting and ensure adequate data quality. The Chief Investigator will inform the sponsor should he/she have concerns which have arisen from monitoring activities, and/or if there are problems with oversight/monitoring procedures. An independent data monitoring committee (DMC) will be set up to deal with patient safety issues related to this project.

The data to be monitored by the DMC will include: language outcome scores (CAT) and Adverse Event Recording Forms. All adverse events will be recorded by the CI and passed on to the DMC and will follow the UCL protocol for reporting of adverse events in a single centre trial. The main function of the committee will be to determine if there is an excess of seizures (adverse events) in either patient group. There are no plans to stop the project early unless this is due to an excess of adverse events.

02

Conditions studied

  • Aphasia, Anomic

Browse trials for

03

In context

Anomia

47 studies on the registry are indexed under Anomia; 9 are open to participants now.

This study's enrollment of 36 is above the median of 24 across 43 interventional studies indexed under Anomia.

Browse Anomia studies →

Lead sponsor

University College London Hospitals is the lead sponsor of 62 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. English native speakers

    1. Over the age of 18
    2. 12 months or more after aphasic stroke
    3. Able to provide

Exclusion criteria

  1. Significant medical or psychiatric co-morbidity

    1. Clinical or neuroimaging evidence of significant multifocal cerebral disease
    2. to tdcs
    3. Contraindications to MRI
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Real tDCS

    fMRI task plus anodal tDCS

    Device: Real tDCS

  • Sham comparator
    Sham tDCS

    fMRI task plus sham tDCS

    Device: Sham tDCS

Interventions

  • DeviceReal tDCS

    Anodal tDCS 2 ma

    Also known as: Brain Stimulation

  • DeviceSham tDCS

    Sham tDCS 2 ma

    Also known as: Brain Stimulation

06

What researchers measure

Primary outcomes

  1. Change in Naming Speed

    change in Tailor-made object naming test,

    Time frame: change from baseline to 20 minutes during and 20 minutes post tDCS intervention

Secondary outcomes

  1. Higher accuracy in naming

    change in scores from tailor-made object naming tests

    Time frame: change from baseline to 20 minutes during and 20 minutes post tDCS intervention

07

Study locations

1 site
  • Institute of Cognitive Neuroscience, University College London
    London, Greater London WC1N 3AZ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Jan 2022, 50 months.

Of 32 non-industry interventional studies with no phase under Anomia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 62. This study's 50 months is above that.

Counting every sponsor, half of 32 studies reached it within 41 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2016
First posted
Oct 24, 2019
StartActual
Nov 30, 2017
Primary completionActual
Jan 30, 2022
CompletionActual
Jan 30, 2022
Last update
May 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04138433
Lead sponsor
University College London Hospitals
Responsible party
Jenny Crinion (Professor Jennifer Crinion, University College, London) — Principal investigator
First posted
Oct 24, 2019
Start date
Nov 30, 2017
Primary completion
Jan 30, 2022
Completion
Jan 30, 2022
Last update
May 11, 2023

Study contacts

Jennifer Crinion, Dr
principal investigator · University College, London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion